Q-linea is about 12 months from launching ASTar - a diagnostic system for rapid phenotypic antibiotic susceptibility testing (AST). The share’s underperformance indicates that investors have yet to grasp the technology’s paradigm-shifting impact and the product portfolio’s high sales potential.